1. Home
  2. BMHL vs VTVT Comparison

BMHL vs VTVT Comparison

Compare BMHL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluemount Holdings Limited Class B Ordinary Shares

BMHL

Bluemount Holdings Limited Class B Ordinary Shares

N/A

Current Price

$5.91

Market Cap

155.4M

Sector

N/A

ML Signal

N/A

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$32.70

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMHL
VTVT
Founded
2016
2015
Country
Hong Kong
United States
Employees
9
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.4M
148.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BMHL
VTVT
Price
$5.91
$32.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$53.00
AVG Volume (30 Days)
3.5K
53.6K
Earning Date
06-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$66.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$14.00
52 Week High
$6.35
$44.00

Technical Indicators

Market Signals
Indicator
BMHL
VTVT
Relative Strength Index (RSI) 64.03 44.44
Support Level $5.58 $30.14
Resistance Level $6.35 $33.76
Average True Range (ATR) 0.31 2.61
MACD -0.07 -0.36
Stochastic Oscillator 82.53 27.27

Price Performance

Historical Comparison
BMHL
VTVT

About BMHL Bluemount Holdings Limited Class B Ordinary Shares

Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: